{"id":955057,"date":"2026-04-27T17:01:32","date_gmt":"2026-04-27T21:01:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/"},"modified":"2026-04-27T17:01:32","modified_gmt":"2026-04-27T21:01:32","slug":"editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/","title":{"rendered":"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., April  27, 2026  (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead\u00a0<em>in vivo<\/em> development candidate, to be a transformative therapy for people living with hyperlipidemia.<\/p>\n<p>The complete list of Editas Medicine presentations is below.<\/p>\n<p>\n        <strong><br \/>\n          <u>American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, May 11-15<\/u><br \/>\n        <\/strong><br \/>\n        \n      <\/p>\n<p>\n        <strong>Oral Presentation:<\/strong><br \/>\n        <br \/>\n        <strong>Title: <\/strong>Preclinical Development of EDIT-401, a Durable <em>In Vivo<\/em> CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C<br \/><strong>Session Date and Time:<\/strong> Thursday, May 14, 3:30 p.m. \u2013 5:00 p.m. EDT<br \/><strong>Session Title:<\/strong> Gene Therapy for Cardiovascular Diseases<br \/><strong>Presentation Room: <\/strong>206AB<br \/><strong>Final Abstract Number:<\/strong> 380<\/p>\n<p>\n        <strong>Poster Presentations:<\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Pharmacokinetics and Pharmacodynamics of <em>In Vivo<\/em> Gene Editing Therapy for Lowering LDL-C in Mice<br \/><strong>Session Date and Time:<\/strong> Thursday, May 14, 5:00 p.m. \u2013 6:30 p.m. EDT<br \/><strong>Session Title:<\/strong> Thursday Poster Reception<br \/><strong>Presentation Room:<\/strong> Exhibit and Poster Hall<br \/><strong>Final Abstract Number:<\/strong> 3423<\/p>\n<p>\n        <strong>Title:<\/strong><br \/>\n        <em>In Vivo<\/em> CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model<br \/><strong>Session Date and Time:<\/strong> Wednesday, May 13, 5:00 p.m. \u2013 6:30 p.m. EDT<br \/><strong>Session Title:<\/strong> Wednesday Poster Reception<br \/><strong>Presentation Room:<\/strong> Exhibit and Poster Hall<br \/><strong>Final Abstract Number:<\/strong> 2324<\/p>\n<p>\n        <strong><br \/>\n          <u>TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, May 11-14<\/u><br \/>\n        <\/strong><br \/>\n        \n      <\/p>\n<p>\n        <strong>Oral Presentation:<\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> Transformative LDL Cholesterol Lowering <em>In Vivo<\/em> CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease<br \/><strong>Session Date and Time:<\/strong> Wednesday, May 13, 8:30 a.m. \u2013 9:00 a.m. EDT<br \/><strong>Session Title:<\/strong> mRNA &amp; Genome Editing: Technology &amp; Applications<\/p>\n<p>\n        <strong><br \/>\n          <u>94<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>th<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u> European Atherosclerosis Society (EAS) Congress, May 24-27<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Oral Presentation:<\/strong><br \/>\n        <br \/>\n        <strong>Title:<\/strong> A Transformative <em>In Vivo<\/em> CRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human Primates<br \/><strong>Session Date and Time:<\/strong> Monday, May 25, 3:45 p.m. \u2013 5:15 p.m. EET\/9:45 a.m. \u2013 11:15 a.m. EDT<br \/><strong>Session Title: <\/strong>New Pathways for Lipid and Lipoprotein Metabolism<br \/><strong>Presentation Room:<\/strong> Nana Hall<br \/><strong>Final Abstract Number:<\/strong> 159<\/p>\n<p>Abstracts can be accessed on the conference websites as they become available, and the presentations will be posted on the Editas Medicine website during the conferences.<\/p>\n<p>\n        <strong>About Editas Medicine<\/strong><br \/>\n        <br \/>As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative <em>in vivo<\/em> medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision <em>in vivo<\/em> gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute\u2019s Cas12a patent estate and Broad Institute and Harvard University\u2019s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDEzMDkxNDEtMzhmNy00YTY4LTg4ODktMzQ0MDE3NjM1NTI1LTEwMzc1OTktMjAyNi0wNC0yNy1lbg==\/tiny\/Editas-Medicine-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor and Media Contacts:\r\nir@editasmed.com\r\nmedia@editasmed.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead\u00a0in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia. The complete list of Editas Medicine presentations is below. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955057","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead\u00a0in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia. The complete list of Editas Medicine presentations is below. &hellip; Continue reading &quot;Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T21:01:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences\",\"datePublished\":\"2026-04-27T21:01:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/\"},\"wordCount\":524,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/\",\"name\":\"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=\",\"datePublished\":\"2026-04-27T21:01:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead\u00a0in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia. The complete list of Editas Medicine presentations is below. &hellip; Continue reading \"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-27T21:01:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences","datePublished":"2026-04-27T21:01:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/"},"wordCount":524,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/","name":"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=","datePublished":"2026-04-27T21:01:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcwNzc1NCM3NTY3OTY4IzIwMjYwMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-to-present-new-preclinical-data-demonstrating-progress-of-edit-401-as-potential-treatment-for-hyperlipidemia-at-upcoming-scientific-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955057"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955057\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}